Markets:

Overview

News

Currencies

International

Treasuries

Pfizer (NY:PFE)

24.90 -0.09 (-0.36%)

Official Closing Price Updated: 7:00 PM EST, Dec 31, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

99 100 Next >

3 Stocks Under $50 We’re Skeptical Of

November 02, 2025

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some...

Via StockStory

Pfizer (PFE) Q3 Earnings: What To Expect

November 02, 2025

Global pharmaceutical company Pfizer (NYSE:PFE) will be announcing earnings results this Tuesday before market open. Here’s what you need to know.

Via StockStory

Topics Artificial Intelligence

Is It Time to Dump Your Shares of Pfizer? ↗

November 02, 2025

Pfizer stock has dropped 50% over the past three years.

Via The Motley Fool

Topics Intellectual Property

AI Unleashes a New Era: Biopharma’s Accelerated Revolution and the Rise of TechBio

November 01, 2025

The biopharmaceutical industry is undergoing an immediate and profound transformation, as Artificial Intelligence (AI) rapidly compresses timelines, drastically reduces costs, and significantly...

Via TokenRing AI

Topics Animal Testing Artificial Intelligence Economy

Retail Investors Now Expect Viking Therapeutics To Bag A Deal After Novo Nordisk, Pfizer Engage In A Bidding War For Rival Metsera ↗

October 30, 2025

Via Stocktwits

Pfizer Sues Novo Nordisk And Metsera To Block The Proposed $6.5 Billion Deal ↗

October 31, 2025

Pfizer sued Metsera and Novo Nordisk on Friday to prevent Novo's proposed $6.5 billion takeover of the smaller company.

Via Investor's Business Daily

Topics Law Enforcement Lawsuit

US Government Shutdown Threatens Deeper Economic Drag, BMO Warns

October 31, 2025

The United States is grappling with the severe economic fallout of a prolonged government shutdown, now stretching through the entire month of October 2025. With federal operations curtailed and...

Via MarketMinute

Topics Economy

Pfizer Files Lawsuit Against Metsera and its Directors and Novo Nordisk for Breach of Merger Agreement

October 31, 2025

From Pfizer Inc.

Via Business Wire

Novo Nordisk Submits Revised Bid For Metsera, Enters A Bidding War With Pfizer ↗

October 30, 2025

Via Stocktwits

Amgen Solidifies Biotech Dividend Prowess with $2.38 Q4 2025 Payout

October 31, 2025

Thousand Oaks, CA – October 31, 2025 – Amgen (NASDAQ: AMGN), a leading biotechnology giant, has declared a quarterly dividend of $2.38 per share for the fourth quarter of 2025. This significant...

Via MarketMinute

Topics Intellectual Property

Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition

October 31, 2025

From Pfizer Inc.

Via Business Wire

Why Bio-Techne (TECH) Stock Is Up Today

October 31, 2025

Shares of life sciences company Bio-Techne (NASDAQ:TECH) jumped 2.8% in the afternoon session after Baird adjusted its price target on the company, signaling a more positive outlook. The investment...

Via StockStory

Topics Artificial Intelligence Supply Chain World Trade

Which S&P500 stocks are the most active on Friday? ↗

October 31, 2025

Let's have a look at what is happening on the US markets on Friday. Below you can find the most active S&P500 stocks in today's session.

Via Chartmill

The AI Imperative: Why Rapid Upskilling is Non-Negotiable for Pharma’s Future

October 31, 2025

The pharmaceutical sector stands at the precipice of a profound transformation, driven by the relentless march of artificial intelligence (AI) and other advanced technologies. As highlighted by...

Via TokenRing AI

Topics Artificial Intelligence Economy

AI Revolutionizes Pharma: Smarter Excipients for Safer, More Potent Drugs

October 31, 2025

San Francisco, CA – October 31, 2025 – Artificial intelligence (AI) is ushering in a transformative era for the pharmaceutical industry, particularly in the often-overlooked yet critical domain of...

Via TokenRing AI

Topics Artificial Intelligence Supply Chain

AI Revolutionizes Pharma Supply Chains: A New Era of Localized Resilience and Efficiency

October 31, 2025

The pharmaceutical industry is experiencing a profound and immediate transformation as Artificial Intelligence (AI) becomes a strategic imperative for localizing supply chains, fundamentally enhancing...

Via TokenRing AI

Topics Artificial Intelligence Economy Fraud

AI Revolutionizes Pharma R&D: A New Era of Accelerated Drug Discovery and Personalized Medicine

October 31, 2025

Artificial intelligence (AI) is ushering in a transformative era for pharmaceutical research and development (R&D), fundamentally reshaping how new medicines are discovered, developed, and brought to...

Via TokenRing AI

Topics Artificial Intelligence Intellectual Property

AI: The Pharmaceutical Sector’s New Catalyst for a Healthier Future

October 31, 2025

The pharmaceutical industry is in the midst of a profound and rapid transformation, driven by the pervasive integration of Artificial Intelligence (AI). What was once a futuristic concept is, by late...

Via TokenRing AI

Topics Animal Testing Artificial Intelligence Economy

Why iRhythm (IRTC) Stock Is Trading Up Today

October 31, 2025

Shares of medical technology company iRhythm Technologies (NASDAQ:IRTC) jumped 3.2% in the afternoon session after it reported strong third-quarter financial results that surpassed expectations and...

Via StockStory

Topics Artificial Intelligence World Trade

AbbVie Beats Third-Quarter Forecasts As Immunology Kingpin Grows 47% ↗

October 31, 2025

AbbVie stock dipped early Friday, though the drug giant easily beat views.

Via Investor's Business Daily

Viking Therapeutics Stock Powers Toward Best Month Of The Year — Wall Street, Retail Bulls Fired Up On Obesity Drug Promise ↗

October 31, 2025

Traders on Stocktwits linked Novo Nordisk’s renewed bid for Metsera to competition from Viking’s obesity drug VK2735, fueling further optimism.

Via Stocktwits

1 Safe-and-Steady Stock with Competitive Advantages and 2 We Turn Down

October 31, 2025

Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.

Via StockStory

Edwards Lifesciences Pops As Third-Quarter Beat Lifts 2025 Guidance ↗

October 30, 2025

Edwards Lifesciences stock jumped late Thursday after the medtech company boosted its 2025 outlook after beating quarterly calls.

Via Investor's Business Daily

Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain ↗

October 30, 2025

As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the GLP-1 gold rush.

Via Benzinga

Topics ETFs

Thursday's session: most active stock in the S&P500 index ↗

October 30, 2025

Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Thursday and uncover the stocks that are leading the way in terms of trading volume and market...

Via Chartmill

Check out the stocks that are attracting the most attention and driving market activity. ↗

October 30, 2025

Let's dive into the action on the US markets on Thursday. Here are the most active stocks that are driving the market today.

Via Chartmill

Novo Nordisk Kicks Off Bloody Battle With Pfizer, Bidding $6.5 Billion On Metsera ↗

October 30, 2025

Novo Nordisk kicked off a battle with Pfizer on Thursday, making an unsolicited $6.5 billion bid for obesity-focused Metsera.

Via Investor's Business Daily

Topics Economy Government

Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless' ↗

October 30, 2025

Novo Nordisk's $9 billion offer for Metsera challenges Pfizer's existing merger deal, prompting sharp criticism and potential legal action.

Via Benzinga

Alnylam Stock Has Already Doubled In 2025. Why It Could Rocket Again On Earnings. ↗

October 30, 2025

The company easily beat third-quarter expectations and issued guidance that widely topped forecasts.

Via Investor's Business Daily

Pfizer Addresses Proposal for Metsera

October 30, 2025

From Pfizer Inc.

Via Business Wire

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.